Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.

What the trial testedas reported · 3,613 people · 2026

Not counted

2.6×1.7× to 4×

Bigger than 9 in 10 for adverse events & safety

As reported

RR 2.62, 95% CI 1.70–4.03

the abstract, start to end

… higher in the semaglutide group (RR 2.62, 95% CI: 1.70-4.03; P = .001).

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

RR 2.621.70–4.03

GLP-1 receptor agonistsAdverse events & safety

1 / 3